Top Life Sciences Companies To Buy For 2014

No sooner had Life Technologies Corp. (NASDAQ: LIFE  ) announced its successful purchase of KDR Biotech last week, then out came Thermo Fisher Scientific (NYSE: TMO  ) with a $13.6 billion bid to buy Life Technologies itself.

This morning, Life Technologies announced that it has signed a definitive agreement to sell itself to Thermo Fisher for $76 per share, or about $13.6 billion in total plus assumption of $2.2 billion in net debt. That assumption raises the deal value to $15.8 billion in total, easily trumping what was being reported last week as an estimated $11 billion bid for Life Technologies from private equity powerhouses Blackstone, Carlyle Group, and KKR.

The deal must be approved by shareholders and needs regulatory approval.

Thermo Fisher CEO Marc N. Casper was quoted in the company press release as saying that "Life Technologies enhances all three elements of our growth strategy: technological innovation, a unique customer value proposition and expansion in emerging markets." Life Technologies and Thermo Fisher say the deal will build on their "technological strengths to accelerate results for life sciences customers working in proteomics, genomics and cell biology."

Hot Blue Chip Companies For 2015: Panasonic Corp (PCRFF)

Panasonic Corporation is a Japan-based electronics manufacturer. The Audio-Visual Computer (AVC) Network segment offers audio and video equipment. The Appliance segment provides household air-conditioning machines. The System Communications segment provides system network and mobile communications-related products and services. The Eco-solutions segment consists of riding, energy system, housing system and others. The Automotive systems segment provides automotive multimedia-related equipment and others. The Device segment provides electronic components, semiconductors and optical devices. The Energy segment provides solar system and lithium-ion batteries. The Others segment consists of health care, manufacturing solutions and PanaHome. On October 1, 2013, it announced it had set up a research and development center in Singapore. In December 2013, it transferred its 66.7% stake in a Japan-based subsidiary. In December 2013, it acquired a Turkey-based company. Advisors' Opinion:

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- Japanese stocks slipped early Monday, with the Nikkei Stock Average (JP:NIK) down 0.1% at 14,298.17, and the Topix dropping 0.4%. Singapore-traded lead futures for the Nikkei Average had suggested a 0.8% gain for the index, but the indicator fell after the Cabinet Office reported fourth-quarter economic growth of 0.3%, flat from the previous quarter and below expectations in separate Reuters and Wall Street Journal/Nikkei surveys. The disappointing economic data also pushed the yen higher, weighing on some exporters, with Panasonic Corp. (JP:6752) (PCRFF) down 1.8%, NEC Corp. (JP:6701) (NIPNF) off 1.3%, and Sony Corp. (JP:6758) (SNE) down 0.7% after S&P downgraded the firm's credit rating to BBB- from BBB with a negative outlook. Shares of Internet retailer Rakuten Inc. (JP:4755) (RKUNF) dropped 12% after announcing plans to buy online messaging and telecom firm Viber Media Inc. for $900 million as well as posting below-consensus full-year profit. Banks were broadly lower, with Mizuho Financial Group Inc. (JP:8411) (MFG) off 1% and Sumitomo Mitsui Financial Group Inc. (JP:8316) (SMFG) off 1.1%, though Daiwa Securities Group Inc. (JP:8601)

Top Life Sciences Companies To Buy For 2014: Arcadis NV (ARCAD)

Arcadis NV is a Netherlands-based international engineering and consultancy firm, providing consultancy, design, engineering and management services in infrastructure, water, environment and buildings. The Company develops, designs, implements, maintains and operates projects for companies and governments. The Company divides its business into four business lines: Infrastructure, which encompasses services for transportations, land development, energy and mining; Water, focused on water planning, wastewater and water management and consulting services; Environment, focused on activities that protect the environment and enhance sustainability, and Buildings, related to homebuilding as well as commercial and industrial buildings and facilities construction. Additionally, it works in partnership with UN-HABITAT, the United Nations agency for human settlements. Advisors' Opinion:

• [By Sofia Horta e Costa]

  Companies like Expedia Inc. (EXPE), which provides online travel booking services, and Arcadis NV (ARCAD), a Dutch designer of bridges and dikes, are likely to increase profit at a faster pace than larger firms during an improving economy, Duret said. Smaller companies are also less leveraged, with U.S. mid-caps holding 46 percent less debt per share than firms listed on the S&P 500, data compiled by Bloomberg show.

Top Life Sciences Companies To Buy For 2014: P & F Industries Inc.(PFIN)

P&F Industries, Inc., through its subsidiaries, manufactures and sells tools and hardware products in the United States. The company operates in two segments, Tools and Other Products (Tools) and Hardware and Accessories (Hardware). The Tools segment manufactures, imports, and sells pneumatic hand tools, primarily for the industrial, retail, and automotive markets. Its product line includes sanders, grinders, drills, saws, impact wrenches, and pavement breakers; compressor air filters; and pipe and bolt dies, pipe taps, wrenches, vises and stands, pipe and tubing cutting equipment, hydrostatic test pumps, and replacement electrical components for pipe cutting and threading machines. This segment sells its products under the Florida Pneumatic, Universal Tool, ATP, Thaxton, THOR, and Eureka brand names to distributors, retailers, and private label customers through in-house sales personnel and manufacturers' representatives. The Hardware segment manufactures and imports door , window, and fencing hardware, including rollers, hinges, window operators, sash locks, custom zinc castings, and door closers. This segment also manufactures and imports interior wood and iron stair components, and related accessories, as well as kitchen and bath hardware; and manufactures stair products and distributes staircase components. Its products are sold through in-house sales personnel and manufacturers? representatives to distributors, retailers, and OEM customers. The company was founded in 1959 and is based in Melville, New York.

Advisors' Opinion:

• [By Monica Gerson]

  P&F Industries (NASDAQ: PFIN) is expected to report its quarterly results.

  INSYS Therapeutics (NASDAQ: INSY) is projected to report its Q1 earnings at $0.28 per share on revenue of $45.63 million.

Top Life Sciences Companies To Buy For 2014: Shire PLC (SHPG)

Shire plc (Shire), incorporated on January 28, 2008, is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. As of December 31, 2012, the Company�� products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), FOSRENOL (lanthanum carbonate), XAGRID (anagrelide hydrochloride), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant) and DERMAGRAFT(Human Fibroblast-Derived Dermal Substitute). As of December 31, 2012, the Company�� products under development included INTUNIV (extended release guanfacine), VYVANSE/VENVANSE (lisdexamfetamine dimesylate), INTUNIV, Guanfacine Carrier Wave, LIALDA (mesalamine)/MEZAVANT (mesalazine), RESOLOR (prucalopride), RESOLOR (prucalopride), SPD 557(M0003), XAGRID, VYVANSE (lisdexamfetamine dimesylate), REPLAGAL (agalsidase alfa), HGT-4510, HGT-2310, HGT-1410, HGT-1110, HGT-3010, and DERMAGRAFT. On January 31, 2012, the United States Food and Drug Administration approved VYVANSE for the maintenance treatment of ADHD in adults. In March 2013, it announced the acquisition Of Premacure AB. In January 2014, Shire Plc sold its DERMAGRAFT assets to Organogenesis Inc. In January 2014, Shire Plc acquired 79.5% interest in ViroPharma Inc.

VANSE/ VENVANSE

VYVANSE is a New Chemical Entity (NCE) and is the pro-drug stimulant for the treatment of ADHD, where the amino acid l-lysine is linked to d-amphetamine. VYVANSE is therapeutically inactive until metabolized in the body. The United Stat! es Food and Drug Administration approved VYVANSE as a once-daily treatment for children aged 6 to 12 with ADHD in February 2007, for adults in April 2008 and for adolescents aged 13 to 17 in November 2010. VYVANSE is available in the United States in six dosage strengths: 20 milligram, 30 milligram, 40 milligram, 50 milligram, 60 milligram and 70 milligram. Health Canada approved VYVANSE for the treatment of ADHD in pediatric patients aged 6 to 12 in February 2009, and for adolescents and adults in November 2010. In April 2012, ANVISA, the Brazilian health authority, granted marketing authorization approval for lisdexamfetamine dimesylate for the treatment of ADHD in children aged 6-12.

ADDERALL XR

ADDERALL XR is an extended release treatment for ADHD, which uses MICROTROL drug delivery technology and is designed to provide once-daily dosing. It is available in 5 milligram, 10 milligram, 15 milligram, 20 milligram, 25 milligram and 30 milligram capsules and can be administered either as a capsule or sprinkled on soft food. The United States Food and Drug Administration has approved ADDERALL XR as a once-daily treatment for children aged 6 to 12 with ADHD, for adults in and for adolescents aged 13 to 17. Teva Pharmaceutical Industries, Ltd. (Teva) and Impax Laboratories, Inc. (Impax) commenced commercial shipment of their authorized generic versions of ADDERALL XR in April and October 2009, respectively. Shire receives royalties from Impax�� sales of authorized generic ADDERALL XR.

INTUNIV

INTUNIV is a selective alpha-2A receptor agonist indicated for the treatment of ADHD. Alpha-2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signalling in the prefrontal cortex (Cell. 2007; 129:397-410). INTUNIV is non-scheduled and has no known potential for abuse or dependence. The United States Food and Drug Administration approved INTUNIV in September 2009, as a once-daily monotherapy treatment of ADHD in children and adolesce! nts aged ! 6 to 17. It is available in 1 milligram, 2 milligram, 3 milligram and 4 milligram tablets.

EQUASYM

Shire has acquired from UCB the worldwide rights (excluding the United States, Canada and Barbados) to EQUASYM (methylphenidate hydrochloride) IR and XL for the treatment of ADHD in children and adolescents aged 6 to 18. At December 31, 2012,EQUASYM XL was commercially available in 10 countries in 10mg, 20mg and 30mg strengths. EQUASYM XL is marketed in Mexico and South Korea under the trade name METADATE CD.

LIALDA/MEZAVANT

LIALDA is indicated for the induction ofmild to moderately active UC and for the maintenance of remission of UC. The addition of the indication for maintenance of remission of ulcerative colitis was approved by Health Canada in February 2011, and by the United States Food and Drug Administration in July 2011. LIALDA is once-daily oral formulation of mesalamine indicated for the induction and maintenance of remission. As of December 31, 2012, LIALDA/MEZAVANT (this product is marketed outside the United States as MEZAVANT) was commercially available in 19 countries either directly or through distributor arrangements.

PENTASA

PENTASA controlled release capsules are approved in the United States (marketed by Shire in the United States and by Ferring outside of the United States) and indicated for the induction of remission and for the treatment of patients with mild to moderately active ulcerative colitis. PENTASA is an ethylcellulose-coated, controlled release capsule formulation designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. PENTASA is available in the United States in 250 milligram and 500 milligram capsules.

RESOLOR

RESOLOR (prucalopride), a 5-HT4 receptor agonists that stimulates gastrointestinal motility and acts primarily on different parts of the lower gastrointestinal tract (enterokinetic). In October 2009, RESOLOR was appr! oved by t! he EMA throughout the European Union as a once daily oral treatment for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. In July 2010, Swissmedic granted RESOLOR marketing authorization in Switzerland for the treatment of idiopathic chronic constipation in adults. RESOLOR is available in milligram and 2 milligram dose strengths, both for once-daily dosing. At December 31, 2012, RESOLOR was available in six European Union countries. Formulated as a chewable tablet, FOSRENOL is available in 500 milligram, 750 milligram and 1,000 milligram dosage strengths.

XAGRID

XAGRID (anagrelide hydrochloride) is marketed in Europe for the reduction of elevated platelet counts in at-risk ET patients. XAGRID has been granted orphan drug status in the European Union. In the United States, anagrelide hydrochloride is sold by the Company under the name AGRYLIN for the treatment of thrombocythemia secondary to a MPD.

REPLAGAL

REPLAGAL is for the treatment of Fabry disease. Fabry disease is a genetic disorder resulting from a deficiency in the activity of the lysosomal enzyme alpha-galactosidase A, which is involved in the breakdown of fats. REPLAGAL is a human alpha-galactosidase A protein made in human cells that replaces the deficient alpha-galactosidase A with an active enzyme to ameliorate certain clinical manifestations of Fabry disease. At December 31, 2012, REPLAGAL was approved in 46 countries.

ELAPRASE

ELAPRASE is a treatment for Hunter syndrome (also known as Mucopolysaccharidosis Type II or MPS II). Hunter syndrome is a genetic disorder mainly affecting males that interferes with the body's ability to break down and recycle waste substances called mucopolysaccharides, also known as glycosaminoglycans (GAGs). ELAPRASE was approved by the United States Food and Drug Administration and granted marketing authorization by the EMA for the long term treatment of patients with Hunter ! syndrome.! ELAPRASE has been granted orphan drug by both the United States Food and Drug Administration and the EMA. ELAPRASE received approval from the Ministry of Health, Labour and Welfare in Japan. At December 31, 2012, ELAPRASE was approved in 51 countries.

VPRIV

VPRIV is a treatment for Type 1 Gaucher disease. Gaucher disease is an inherited genetic disorder, which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. VPRIV was approved by the United States Food and Drug Administration in February 2010, for the long-term treatment of patients with Type 1 Gaucher disease. The EMA approved the marketing authorization for the use of VPRIV in August 2010. VPRIV was authorized as an orphan medicine through the Centralised Procedure in Europe. At December 31, 2012, VPRIV was approved in 38 countries.

FIRAZYR

FIRAZYR is a peptide-based therapeutic developed for the symptomatic treatment of acute attacks of HAE. In July 2008 the EMA granted marketing authorization throughout the European Union for the use of FIRAZYR for the symptomatic treatment of acute attacks of HAE, and in May 2011 approved FIRAZYR for self-administration after training in subcutaneous injection technique by a healthcare professional. In August 2011, the United States Food and Drug Administration granted marketing approval for FIRAZYR in the United States for treatment of acute attacks of HAE in adults aged 18 and older. After injection training, patients may self-administer FIRAZYR. FIRAZYR has been granted orphan drug by both the United States Food and Drug Administration and the EMA. At December 31, 2012, FIRAZYR was approved in 38 countries globally.

DERMAGRAFT

DERMAGRAFT is a bio-engineered skin substitute that assists in restoring damaged tissue. DERMAGRAFT is indicated for use in the treatment of full-thickness Diabetic foot ulcers (DFU) greater than six weeks in duration, which extend through the dermis, but without tendon, muscle, joint capsu! le, or bo! ne exposure. DERMAGRAFT is approved by the United States Food and Drug Administration as a Class III medical device for the treatment of DFUs. DERMAGRAFT is also approved for the treatment of DFUs in South Africa, Israel and Singapore.

The Company competes with Shionogi & Co., Ltd., Janssen-Cilag, Novartis, Medice, Eli Lilly, Warner Chilcott, Synergy Pharmaceuticals, Inc., ARYx Therapeutics, Theravance, Inc., Sucampo Pharmaceuticals, Inc., Albireo, Actelion Ltd., Protalix BioTherapeutics Inc, Genzyme, CSL Behring, Pharming Group N.V., ViroPharma, Dyax Corporation, Organogenesis, Healthpoint, Soluble System, KCI, Smith & Nephew, Aurobindo and Apotex.

Advisors' Opinion:

• [By Johanna Bennett]

  British drug maker Shire (SHPG) turned up its nose at the $46.5 billion offer by U.S. rival AbbVie (ABBV), in the latest move by a U.S. company to pursue a deal for a company with a lower tax rate. Simply put, Shire says the bid is to low and released ambitious new targets to more than double its annual sales to $10 billion by 2020.

  What will it take to get the deal done?

  Leerink analyst Jason Gerberry says AbbVie�� cash and stock offer is lacking in certain areas, namely the stock component is too high and there�� no contingent right value to reward Shire shareholders for pipeline assets that could pop down the road. He writes:

  We believe the race for doing tax inversions will only accelerate, which works in SHPG�� favor, meaning demand for SHPG will be high and SHPG should seriously considering accepting a slightly higher offer that is more cash-rich and also allows shareholders to enjoy the potential upside if products like Premiplex or lifitegrast get approved. Next steps: ABBV will need to announce its firm intention to make another offer by 7/18. Other potential acquirers we could envision stepping in include AGN, PFE, and BMY.

  AbbVie said Friday that it had made three cash-and-share proposals to the board of Shire, with the latest valued at $78.87 for each Shire share. The North Chicago, Ill.-based drug maker said discussions were no longer ongoing and offered no guarantee of another offer.

  AbbVie’s proposal comes amid a wave of interest in such so-called tax inversion deals, most prominently Pfizer�� (PFE) failed $120 billion attempt to buy AstraZeneca (AZN). U.S. medical-device company Medtronic (MDT) on Sunday agreed to buy the U.K.‘s Covidien (COV) for $42.9 billion, also in part to lower its tax rate.

  Buying Shire is about more than lowering AbbVie�� tax bill. The deal reduced Shire�� reliance on Humira sales before the patent protecting the arthritis drug expires in 2016.

  But th

• [By Ben Levisohn]

  Nevertheless, while we believe that the rejection vote is a setback to Valeant, we remain confident that Valeant will either ultimately succeed in its bid to acquire Allergan near-term or seek to consummate another transaction elsewhere. We note that thus far it does not appear that Allergan has much strategic wiggle room, having already been rebuffed by potential white knights such as Sanofi S.A. (SNY) and Johnson & Johnson (JNJ) and with little chance, in our view, of making a meaningful acquisition of its own, such as the purchase of Shire (SHPG).

• [By Alexander Maxwell]

  The market for the treatment of chronic diabetic foot ulcers has been growing and larger companies have been taking notice. Many large pharmaceutical companies have their own treatments for chronic diabetic foot ulcers. The space has also caused some major acquisitions. In 2011, Shire� (NASDAQ: SHPG  ) acquired�a drug called Dermagraft for the treatment of slow-healing diabetic foot ulcers, through its $750 million acquisition of�Advanced BioHealing. Dermagraft has been a rather lucrative product for Shire, with $153.8 million in sales�last year. As the market continues to grow, I would look for more partnerships with large pharmaceutical companies, and of course more research and development dollars being devoted toward the chronic diabetic foot ulcers indication.

• [By Jon C. Ogg]

  Shire PLC (NASDAQ: SHPG) was raised to Overweight from Neutral at J.P. Morgan.

  Telecom Italia SpA (NYSE: TI) was raised to Neutral from Underperform at J.P. Morgan.

Top Life Sciences Companies To Buy For 2014: Rogue Resources Inc (RRS)

Rogue Resources Inc., formerly Rogue Iron Ore Corp., is an exploration-stage company. The Company is engaged in acquiring, exploring, and evaluating mineral properties located in Canada and the United States. The Company owns a 100% interest in Radio Hill Iron Ore property. The Radio Hill Iron Ore property consists of a 12,000 hectare land package located 85 kilometer southwest of Timmins, Ontario. Langmuir Property located seven kilometers by road from Liberty Mines Nickel mill, which has a capacity of 2000 tons/day. Langmuir Property is consists of 74 contiguous unpatented mining claims of 856 units (13,841 hectares). The Langmuir Property includes over 30 kilometer of terrain consists of ultramafic and mafic flows and sills for hosting nickel, copper and platinum group mineralization (PGM). As of April 1, 2012, the Company completed 31 drill holes at Radio Hill for a total of 7,828 meters. In March 2013, it completed the spin off its Rapier Gold Inc unit. Advisors' Opinion:

• [By Jonathan Morgan]

  Randgold Resources Ltd. (RRS), a gold miner in Africa, declined 5.6 percent to 4,428 pence. Fresnillo Plc, the world�� biggest primary silver producer, sank 11 percent to 924.5 pence after cutting its interim dividend by 68 percent from a year earlier because of a slump in precious-metal prices.

Top Life Sciences Companies To Buy For 2014: Agilent Technologies Inc (A)

Agilent Technologies, Inc. (Agilent), incorporated on May 5, 1999, is a measurement company providing bio-analytical and electronic measurement solutions to the communications, electronics, life sciences and chemical analysis industries. During the fiscal year ended October 31, 2011 (fiscal 2011), it had three business segments: electronic measurement business, chemical analysis business and life sciences business. Its electronic measurement business addresses the communications, electronics and other industries. Agilent�� chemical analysis business focuses on the petrochemical, environmental, forensics and food safety industries. Its life sciences business focuses on the pharmaceutical, biotechnology, academic and Government, bio-agriculture and food safety industries. In addition to its three businesses, it conducts research through Agilent Technologies Laboratories (Agilent Labs). In fiscal 2011, the Company acquired A2 Technologies, Lab901 and Biocius Life Sciences Inc. On December 21, 2011, the Company acquired BioSystem Development business and P.V.R. s.r.l., a vacuum pump manufacturer. In February 2012, the Company acquired software solutions and technology for device-level modeling and validation from Accelicon Technologies. In June 2012, the Company acquired cancer diagnostics company, Dako. In August 2012, the Company acquired Aurora SFC Systems, Inc.

Electronic Measurement Business

The Company�� electronic measurement business provides electronic measurement instruments and systems, software design tools and related services that are used in the design, development, manufacture, installation, deployment and operation of electronics equipment, and microscopy products. Related services include start-up assistance, instrument productivity and application services and instrument calibration and repair. It also offers customization, consulting and optimization services throughout the customer's product lifecycle. It sells products and services applicable to a rang! e of communications networks and systems, including wireless communications and microwave networks, voice, broadband, data, and fiber optic networks. Test products include Electronic Design Automation (EDA) software, vector and signal analyzers, signal generators, vector network analyzers, one box testers, oscilloscopes, logic and protocol analyzers, and bit-error ratio testers.

The Company�� wireless communications and microwave network products include radio frequency and microwave test instruments and electronic design automation software tools. These products are required for the design and production of wireless network products, communications links, cellular handsets and base stations. It provides handheld products for the installation and maintenance of wireless networks. Its electronic design automation software tools and instruments are used by radio frequency integrated circuit design engineers to model, simulate and analyze communications product designs at the circuit and system levels.

The Company�� suite of fiber optic test products measure and analyze a range of optical and electrical parameters in fiber optic networks and their components. Components which can be tested with Agilent solutions include source lasers, optical amplifiers, filters and other passive components. Test products include optical component analyzers, optical power meters and optical spectrum analyzers. It sells the products into the general purpose test market, including general purpose instruments, modular instruments and test software, digital test products, semiconductor and board test solutions, electronics manufacturing test equipment, atomic force microscopes and radio frequency and network surveillance solutions. The Company�� general purpose products include spectrum analyzers, network analyzers, signal generators, logic analyzers, digitizing oscilloscopes, voltmeters, multimeters, frequency counters, bench and system power supplies, function generators and waveform synthesizers. Modular! instrume! nts and test software are used by the designers and manufacturers of electronic devices as the building blocks of systems that can be configured for a range of test applications.

The Company�� digital test products are used by research and development engineers across a range of industries to validate the function and performance of their digital product and system designs. These designs include a range of products from digital control circuits to high speed systems, such as computer servers and the gaming consoles. The test products offered include oscilloscopes, logic and serial protocol analyzers, logic-signal sources and data generators.

The Company�� semiconductor and board test solutions enable customers to develop and test semiconductors, test and inspect printed circuit boards, perform functional testing, and measure position and distance information to the sub-nanometer level. It is a supplier of parametric test instruments and systems used to examine semiconductor wafers during the manufacturing process. Its in-circuit test system helps identify quality defects, such as faulty or incorrect parts, that affect electrical performance. Its laser interferometer measurement systems provide precise position or distance information for dimensional measurements. Its atomic force microscopes (AFM) are imaging devices. An AFM allows researchers to observe and manipulate molecular and atomic level features. Its portfolio of AFM products provides customers with tools for a range of nanotechnology applications, including semiconductor, data storage, polymers, materials science and life science studies. The Company�� surveillance systems and subsystems are used by defense and government engineers and technicians to detect, locate and analyze signals of interest. The products offered include receivers for detecting radio frequency signals, probes for detecting wire line signals and software that enables the identification and analysis of these signals. Agilent's electronic measureme! nt custom! ers include contract manufacturers of electronic products, handset manufacturers and network equipment manufacturers who design, develop, manufacture and install network equipment, service providers who implement, maintain and manage communication networks and services, and companies who design, develop, and manufacture semiconductors and semiconductor lithography systems. Its customers use its products to conduct research and development, manufacture, install and maintain radio frequency, microwave frequency, digital, semiconductor, and optical products and systems and conduct nanotechnology research.

The Company competes with Aeroflex Incorporated, Anritsu Corporation, Ansys Corporation, EXFO Electro-Optical Engineering, Inc., National Instruments Corporation, Rohde & Schwartz GmbH & Co. KG, Spirent plc, Danaher Corporation, Bruker Corporation, LeCroy Corporation, Teradyne, Inc., Test Research Inc. and Zygo Corporation.

Chemical Analysis Business

The Company�� chemical analysis business provides application-focused solutions that include instruments, software, consumables and services that enable customers to identify, quantify and analyze the physical and chemical properties of substances and products. Its product categories in chemical analysis include gas chromatography (GC) systems, columns and components; gas chromatography mass spectrometry (GC-MS) systems; inductively coupled plasma mass spectrometry (ICP-MS) instruments; atomic absorption (AA) instruments; inductively coupled plasma optical emission spectrometry (ICP-OES) instruments; software and data systems; vacuum pumps and measurement technologies; services and support for its products. Agilent provides custom or standard analyzers configured for specific chemical analysis applications, such as detailed speciation of a complex hydrocarbon stream, calculation of gas calorific values in the field, or analysis of a new bio-fuel formulation. It also offers related software, accessories and consumable ! products ! for these and other similar instruments. Its MS products incorporate technologies for measuring mass, including single-quadrupole, triple-quadrupole, and ion trap mass spectrometers. It combines its mass spectrometers with other instruments to instruments, such as GC/MS, and ICP-MS. It also offers related software, accessories and consumable products for these and other similar instruments. The Company�� spectroscopy instruments include atomic absorption (AA) spectrometers, inductively coupled plasma-optical emissions spectrometers (ICP-OES), inductively coupled plasma-mass spectrometers (ICP-MS), fluorescence spectrophotometers, ultraviolet-visible (UV-Vis) spectrophotometers, Fourier Transform infrared (FT-IR) spectrophotometers, near-infrared (NIR) spectrophotometers, Raman spectrometers and sample automation products. It also offers related software, accessories and consumable products for these and other similar instruments.

The Company�� vacuum technologies products are used to create, control, measure and test vacuum environments in life science, industrial and scientific applications where clean and vacuum environments are needed. Products include a range of vacuum pumps, including diffusion, turbomolecular and ion getter; intermediate vacuum pumps, including rotary vane, sorption and dry scroll, vacuum instrumentation, including vacuum control instruments, sensor gauges and meters, and vacuum components, including valves, flanges and other mechanical hardware. Its products also include helium mass spectrometry and helium-sensing leak detection instruments used to identify and measure leaks in hermetic or vacuum environments. The Company offers a range of services, including an exchange and rebuild program, assistance with the design and integration of vacuum systems, applications support and training in basic and advanced vacuum technologies. The Company offers a range of consumable products, which support its technology platforms, including sample preparation consumables, suc! h as soli! d phase extraction (SPE) and filtration products, self manufactured GC and LC columns, chemical standards, and instrument replacement parts. Consumable products also include scientific instrument parts and supplies, such as filters and fittings for GC systems; xenon lamps and cuvettes for UV-Vis-NIR, fluorescence, FT-IR and Raman spectroscopy instruments; and graphite furnace tubes, hollow cathode lamps and specialized sample introduction glassware for its AA, ICP-OES and ICP-MS products.

The Company competes with Bruker Corporation, PerkinElmer Inc., Shimadzu Corporation and Thermo Fisher Scientific Inc.

Life Sciences Business

The Company�� life sciences business provides application-focused technologies and solutions, which include instruments, software, consumables and services. Its product categories include liquid chromatography, mass spectrometry, microarrays, polymerase chain reaction (PCR) instrumentation, bioreagents, electrophoresis, software and informatics, nuclear magnetic resonance (NMR) and magnetic resonance imaging (MRI) systems, and, consumables and services. The Agilent liquid chromatograph (LC) portfolio is modular in construction and can be configured as analytical and preparative systems. Agilent's liquid chromatography/ mass spectrometer (LC/MS) portfolio includes instruments built around five analyzer types, such as single quadrupole, triple quadrupole, ion trap, time-of-flight (TOF) and quadrupole time-of-flight (QTOF). It is a provider of microarray-based, genomics research solutions. It provides products for sequencing platforms. Its portfolio of PCR instrumentation, reagents and kits, coupled with its other products, such as microarrays and target enrichment systems for sequencing, provides a range of workflow solutions to customers in the genomics marketplace.

Agilent is a supplier of electrophoretic separation solutions. The 2100 Bioanalyzer analyzes biomolecules or cells in microfluidic networks of channels and wells etched i! nto glass! chips. The 3100 OFFGEL Fractionator resolves proteins or peptides by isoelectric point with liquid-phase recovery. It provides software for instrument control, data acquisition, data analysis, laboratory content and business process management, and informatics. With OpenLab, Agilent has open architecture, which enables capture, analyze, and share scientific data throughout the lab and across the enterprise. It offers a range of consumable products, which support its LC, and MS technology platforms. These consumable products include sample preparation products; self manufactured LC columns and instrument replacement parts, and consumable supplies to meet its customers' analysis needs. It offers a range of startup, operational, educational and compliance support services for measurement and data handling systems. Its support services include maintenance, troubleshooting, repair and training for all of its chemical and bioinstrumentation analysis hardware and software products.

The Company competes with Affymetrix Inc., Bruker Corp., Danaher Corporation, Illumina, Inc., Life Technologies Corp., Thermo Fisher Scientific Inc. and Waters Corp.

Advisors' Opinion:

• [By CRWE]

  Agilent Technologies Inc. (NYSE:A) reported that it was awarded a significant patent for comparative genomic hybridization methods. CGH methods help researchers study genetics and cancer in both basic and clinical research.

• [By Philip Springer]

  The U.S. economy grew, sort of, at a miniscule annual rate of 0.1 percent in the first quarter, according to the Commerce Dept. This preliminary reading, the first of three, was far below pessimistic expectations. This underperformance has occurred several times since the on-again, off-again recovery officially began in June 2009.
  
  No wonder U.S. government bond yields have declined this year, contrary to most expectations, with the 10-year Treasury going from 3 percent to as low as 2.6 percent.
  
  The first quarter’s economic weakness was attributed primarily to a 7.6 percent decline in exports, partly because of economic weakness in Europe and Asia. Poor weather, a favorite excuse for everything that went wrong during the winter, probably played a part in the export slump.
  
  Also noteworthy, however: Business spending on equipment fell at a 5.5 percent annual pace in the first three months of the year, the largest decline since 2009.
  
  Regardless of the causes, the tepid (to be generous) GDP reading marks a continuation of the still-sluggish growth in the current five-year economic expansion.
  
  The report came right before the Federal Reserve announced that it is continuing to reduce, or taper, its bond purchases to $45 billion a month, from the original $85 billion. The Fed says it’s starting to see faster growth after the harsh winter.
  
  The Fed also maintained its guidance on short-term interest rates, saying they would remain near zero for a “considerable time” after the bond-buying program ends later this year. The current expectation is that the Fed won’t start to raise interest rates until well into 2015.
  
  However, evidence of a possible economic rebound came the next day, May 2. The federal government�� jobs report for April showed a jump of 288,000, with a sharp decline in the official unemployment rate to 6.3 percent.
  
  Meanwhile, corporate profits continue to grow, albeit modest